Krystal Biotech Adjusts Valuation Amid Strong Financial Performance and Growth Indicators

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting a revision in its score. This change is primarily attributed to a shift in its valuation grade, which has transitioned from a classification of expensive to fair.
Key financial metrics indicate a robust performance, with a P/E ratio of 27 and a PEG ratio of 0.25, suggesting a favorable growth outlook relative to its earnings. The company has also reported a strong return on capital employed (ROCE) of 36.18% and a return on equity (ROE) of 14.98%, highlighting effective management of its resources.

Additionally, Krystal Biotech has demonstrated consistent financial strength, achieving positive results for the last seven consecutive quarters. The operating cash flow reached a notable USD 195.4 million, while the net profit for the half-year stood at USD 74.07 million, reflecting significant growth.

With institutional holdings at 100%, the company benefits from the analytical capabilities of these investors, further solidifying its market position.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.